Gen2C

Gen2C is a South Korean biotechnology company specializing in the development of next-generation gene therapies using its proprietary adeno-associated virus (AAV) vector platform. The company focuses on engineering novel AAV capsids with improved tissue specificity, reduced immunogenicity, and enhanced transduction efficiency compared to traditional vectors. Its primary therapeutic focus areas include ophthalmology, particularly wet age-related macular degeneration and retinitis pigmentosa, as well as central nervous system disorders. By leveraging its capsid engineering platform, Gen2C aims to overcome the current limitations of first-generation gene delivery systems to provide more effective and safer treatments for chronic diseases. The company is currently in the pre-clinical stage with several lead candidates undergoing optimization and validation. Gen2C has secured significant venture capital funding to advance its pipeline toward clinical trials.